Dustin Higgins, DO
Endocrinology, Diabetes & Metabolism · Quincy, ILNPI 1306157409
Payments from drug & device makers
Across 626 payments — averaging $38.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$16K
- Amgen$2K
- Abbott$1K
- AstraZeneca$1K
- Lilly USA, LLC$768
- Corcept Therapeutics$657
- plus $3K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 157 | $15,745 |
| Amgen(2 entities) | 17 | $1,568 |
| Abbott | 116 | $1,161 |
| AstraZeneca(2 entities) | 58 | $1,031 |
| Lilly USA, LLC | 50 | $768 |
| Corcept Therapeutics | 39 | $657 |
| Sanofi-aventis U.S. LLC | 33 | $487 |
| Insulet Corporation | 21 | $340 |
| Xeris Pharmaceuticals, Inc. | 17 | $335 |
| Boehringer Ingelheim | 22 | $325 |
| Bayer | 17 | $274 |
| Tandem Diabetes Care, Inc. | 10 | $201 |
| Johnson & Johnson | 13 | $176 |
| Radius Health, Inc. | 9 | $175 |
| Medtronic | 11 | $153 |
| Dexcom, Inc. | 6 | $109 |
| Sequel Med Tech, LLC | 6 | $106 |
| Merck | 7 | $105 |
| AbbVie | 4 | $65 |
| Recordati_rare_diseases_inc. | 3 | $62 |
| Amarin Pharma, Inc. | 4 | $60 |
| Welch Allyn | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Optos, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
How this compares
$24,002 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Quincy
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
- Ammar BayrakdarEvergreen Park$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.